Postfinasteride syndrome (PFS) is a term recently coined to characterize a constellation of reported undesirable side effects described in postmarketing reports and small uncontrolled studies that developed during or after stopping finasteride treatment, and persisted after drug discontinuation. Symptoms included decreased libido, erectile dysfunction, sexual anhedonia, decreased sperm count, gynecomastia, skin changes, cognitive impairment, fatigue, anxiety, depression, and suicidal ideation. The aim of this study is to review the existing medical literature for evidence-based research of permanent sexual dysfunction and mood changes during treatment with 5-alpha-reductase inhibitors including finasteride and dutasteride.

Keywords:
Dutasteride, Finasteride, Side effects, Psychiatric adverse effects, Physical adverse effects, Permanent sexual dysfunction, Psyche
1.
Wilton L, Pearce G, Edet E, Freemantle S, Stephens MD, Mann RD: The safety of finasteride used in benign prostatic hypertrophy: a non-interventional observational cohort study in 14,772 patients. Br J Urol 1996;78:379-384.
2.
Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, et al: Can finasteride reverse the progress of benign prostatic hyperplasia? A two-year placebo-controlled study. The Scandinavian BPH Study Group. Urology 1995;46:631-637.
3.
Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al: The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
4.
Wessells H, Roy J, Bannow J, Grayhack J, Matsumoto AM, Tenover L, et al: Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia. Urology 2003;61:579-582.
5.
Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, et al: Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology 1999;54:670-678.
6.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, et al: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185-1191.
7.
Traish AM, Hassani J, Guay AT, Zitzmann M, Hansen ML: Adverse side effects of 5α-reductase inhibitors therapy: persistent diminished libido and erectile dysfunction and depression in a subset of patients. J Sex Med 2011;8:872-884.
8.
Canguven O, Burnett AL: The effect of 5 alpha-reductase inhibitors on erectile function. J Androl 2008;29:514-523.
9.
Moinpour CM, Darke AK, Donaldson GW, Thompson IM, Langley C, Ankerst DP, et al: Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007;99:1025-1035.
10.
Nickel JC, Fradet Y, Boake RC, Pommerville PJ, Perreault JP, Afridi SK, et al: Efficacy and safety of finasteride therapy for benign prostatic hyperplasia: results of a 2-year randomized controlled trial (the PROSPECT study). PROscar Safety Plus Efficacy Canadian Two year Study. CMAJ 1996;155:1251-1259.
11.
McConnell JD, Bruskewitz R, Walsh P, Andriole G, Lieber M, Holtgrewe HL, et al: The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. N Engl J Med 1998;338:557-563.
12.
Irwig MS, Kolukula S: Persistent sexual side effects of finasteride for male pattern hair loss. J Sex Med 2011;8:1747-1753.
13.
McGahuey CA, Gelenberg AJ, Laukes CA, Moreno FA, Delgado PL, McKnight KM, et al: The Arizona Sexual Experience Scale (ASEX): reliability and validity. J Sex Marital Ther 2000;26:25-40.
14.
Irwig MS: Persistent sexual side effects of finasteride: could they be permanent? J Sex Med 2012;9:2927-2932.
15.
Mondaini N, Gontero P, Giubilei G, Lombardi G, Cai T, Gavazzi A, et al: Finasteride 5 mg and sexual side effects: how many of these are related to a nocebo phenomenon? J Sex Med 2007;4:1708-1712.
16.
Romeo E, Ströhle A, Spalletta G, di Michele F, Hermann B, Holsboer F, et al: Effects of antidepressant treatment on neuroactive steroids in major depression. Am J Psychiatry 1998;155:910-913.
17.
Van Broekhoven F, Verkes RJ: Neurosteroids in depression: a review. Psychopharmacology (Berl) 2003;165:97-110.
18.
Finn DA, Beadles-Bohling AS, Beckley EH, Ford MM, Gililland KR, Gorin-Meyer RE, et al: A new look at the 5alpha-reductase inhibitor finasteride. CNS Drug Rev 2006;12:53-76.
19.
Dubrovsky B: Neurosteroids, neuroactive steroids, and symptoms of affective disorders. Pharmacol Biochem Behav 2006;84:644-655.
20.
Charalampopoulos I, Remboutsika E, Margioris AN, Gravanis A: Neurosteroids as modulators of neurogenesis and neuronal survival. Trends Endocrinol Metab 2008;19:300-307.
21.
Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, et al: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA 1998;95:3239-3244.
22.
Lephart ED: Age-related changes in brain and pituitary 5 alpha-reductase with finasteride (Proscar) treatment. Neurobiol Aging 1995;16:647-650.
23.
Kokate TG, Banks MK, Magee T, Yamaguchi S, Rogawski MA: Finasteride, a 5alpha-reductase inhibitor, blocks the anticonvulsant activity of progesterone in mice. J Pharmacol Exp Ther 1999;288:679-684.
24.
Barrett-Connor E, Von Mühlen DG, Kritz-Silverstein D: Bioavailable testosterone and depressed mood in older men: the Rancho Bernardo Study. J Clin Endocrinol Metab 1999;84:573-577.
25.
Cecchin E, De Mattia E, Mazzon G, Cauci S, Trombetta C, Toffoli G: A pharmacogenetic survey of androgen receptor (CAG)n and (GGN)n polymorphisms in patients experiencing long term side effects after finasteride discontinuation. Int J Biol Markers 2014;29:e310-e316.
26.
Caruso D, Abbiati F, Giatti S, Romano S, Fusco L, Cavaletti G, et al: Patients treated for male pattern hair with finasteride show, after discontinuation of the drug, altered levels of neuroactive steroids in cerebrospinal fluid and plasma. J Steroid Biochem Mol Biol 2015;146:74-79.
27.
Ali AK, Heran BS, Etminan M: Persistent sexual dysfunction and suicidal ideation in young men treated with low-dose finasteride: a Pharmacovigilance Study. Pharmacotherapy 2015;35:687-695.
28.
Rahimi-Ardabili B, Pourandarjani R, Habibollahi P, Mualeki A: Finasteride induced depression: a prospective study. BMC Clin Pharmacol 2006;6:7.
29.
Irwig MS: Depressive symptoms and suicidal thoughts among former users of finasteride with persistent sexual side effects. J Clin Psychiatry 2012;73:1220-1223.
30.
Ganzer CA, Jacobs AR, Iqbal F: Persistent sexual, emotional, and cognitive impairment post-finasteride: a survey of men reporting symptoms. Am J Mens Health 2015;9:222-228.
31.
Altomare G, Capella GL: Depression circumstantially related to the administration of finasteride for androgenetic alopecia. J Dermatol 2002;29:665-669.
32.
Ganzer CA, Jacobs AR: Emotional consequences of finasteride: fool's gold. Am J Mens Health 2016, Epub ahead of print.
33.
Lee SC, Ellis RJ: Male breast cancer during finasteride therapy. J Natl Cancer Inst 2004;96:338-339.
34.
Sasco AJ, Lowenfels AB, Pasker-de Jong P: Review article: epidemiology of male breast cancer. A meta-analysis of published case-control studies and discussion of selected aetiological factors. Int J Cancer 1993;53:538-549.
35.
Thompson IM, Tangen CM, Goodman PJ, Lucia MS, Klein EA: Chemoprevention of prostate cancer. J Urol 2009;182:499-507.
36.
Debruyne F, Barkin J, van Erps P, Reis M, Tammela TLJ, Roehrborn C: Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol 2004;46:488-494.
37.
Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al: Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010;362:1192-1202.
38.
Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, et al: The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010;57:123-131.
39.
Traish AM, Mulgaonkar A, Giordano N: The dark side of 5α-reductase inhibitors' therapy: sexual dysfunction, high Gleason grade prostate cancer and depression. Korean J Urol 2014;55:367-379.
40.
Kaplan SA, Chung DE, Lee RK, Scofield S, Te AE: A 5-year retrospective analysis of 5α-reductase inhibitors in men with benign prostatic hyperplasia: finasteride has comparable urinary symptom efficacy and prostate volume reduction, but less sexual side effects and breast complications than dutasteride. Int J Clin Pract 2012;66:1052-1055.
41.
McConnell JD, Roehrborn CG, Bautista OM, Andriole GL, Dixon CM, Kusek JW, et al: The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 2003;349:2387-2398.
42.
Shenoy NK, Prabhakar SM: Finasteride and male breast cancer: does the MHRA report show a link? J Cutan Aesthet Surg 2010;3:102-105.
43.
Lai J-J, Chang P, Lai K-P, Chen L, Chang C: The role of androgen and androgen receptor in skin-related disorders. Arch Dermatol Res 2012;304:499-510.
44.
Seo YJ, Li ZJ, Choi DK, Sohn KC, Kim HR, Lee Y, et al: Regional difference in sebum production by androgen susceptibility in human facial skin. Exp Dermatol 2014;23:70-72.
45.
Chiriacò G, Cauci S, Mazzon G, Trombetta C: An observational retrospective evaluation of 79 young men with long-term adverse effects after use of finasteride against androgenetic alopecia. Andrology 2016;4:245-250.
© 2016 S. Karger AG, Basel
2016
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.